Ann: Agreement Signed for Sale of Lyramid Limited, page-287

I doubt that any assets have been transferred physically as a result of the sale. In the near term at least I expect Lyramid’s office will remain down the corridor from Cellmid’s, staff will remain in their same chairs, and antibodies still will be stored in the same freezers. The difference is that now funded by outsiders those antibody vials can be taken out and put to use wherever appropriate.

I assume Lyramid remains an Australian registered company for tax purposes, with any local R&D expenses qualifying for ATO refunding. With most of the income support paid to its owner likely to derive from different international sources, and costs being met by international collaborators, there might well be an advantage in its owner being registered in a secrecy jurisdiction.

Good advice about putting the feet up, Ozjin. Enough from me. Other work to do unfortunately.